Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALDX |
---|---|---|
09:32 ET | 6549 | 5.27 |
09:43 ET | 100 | 5.295 |
09:45 ET | 550 | 5.31 |
09:50 ET | 938 | 5.3291 |
09:52 ET | 200 | 5.32 |
09:54 ET | 400 | 5.3 |
09:56 ET | 4263 | 5.25 |
10:03 ET | 3804 | 5.23 |
10:06 ET | 750 | 5.2201 |
10:10 ET | 1051 | 5.2 |
10:12 ET | 1500 | 5.21 |
10:14 ET | 1891 | 5.26 |
10:19 ET | 900 | 5.28 |
10:24 ET | 200 | 5.27 |
10:28 ET | 500 | 5.25 |
10:32 ET | 279 | 5.23 |
10:33 ET | 427 | 5.24 |
10:35 ET | 114 | 5.2599 |
10:37 ET | 1600 | 5.28 |
10:42 ET | 100 | 5.27 |
10:44 ET | 700 | 5.28 |
10:51 ET | 1812 | 5.3 |
10:53 ET | 1620 | 5.31 |
10:55 ET | 740 | 5.3 |
11:02 ET | 2318 | 5.32 |
11:04 ET | 100 | 5.32 |
11:08 ET | 625 | 5.32 |
11:09 ET | 3000 | 5.3 |
11:13 ET | 100 | 5.3 |
11:15 ET | 1094 | 5.31 |
11:18 ET | 1100 | 5.3 |
11:20 ET | 500 | 5.29 |
11:22 ET | 968 | 5.27 |
11:24 ET | 387 | 5.26 |
11:26 ET | 200 | 5.24 |
11:27 ET | 100 | 5.25 |
11:29 ET | 600 | 5.24 |
11:36 ET | 800 | 5.25 |
11:40 ET | 100 | 5.24 |
11:42 ET | 350 | 5.25 |
11:49 ET | 100 | 5.23 |
11:51 ET | 1370 | 5.235 |
11:56 ET | 1421 | 5.26 |
12:02 ET | 300 | 5.26 |
12:03 ET | 400 | 5.27 |
12:07 ET | 689 | 5.29 |
12:09 ET | 100 | 5.28 |
12:18 ET | 600 | 5.29 |
12:20 ET | 700 | 5.29 |
12:25 ET | 2002 | 5.32 |
12:32 ET | 200 | 5.32 |
12:34 ET | 1100 | 5.3231 |
12:38 ET | 200 | 5.325 |
12:39 ET | 2900 | 5.315 |
12:41 ET | 900 | 5.33 |
12:45 ET | 203 | 5.33 |
12:50 ET | 100 | 5.33 |
12:52 ET | 400 | 5.33 |
12:56 ET | 250 | 5.32 |
12:57 ET | 100 | 5.325 |
12:59 ET | 250 | 5.33 |
01:06 ET | 300 | 5.32 |
01:08 ET | 21360 | 5.34 |
01:10 ET | 20062 | 5.34 |
01:12 ET | 7792 | 5.35 |
01:14 ET | 2400 | 5.37 |
01:15 ET | 2507 | 5.37 |
01:17 ET | 3725 | 5.3701 |
01:19 ET | 17064 | 5.365 |
01:24 ET | 700 | 5.37 |
01:26 ET | 4878 | 5.35 |
01:28 ET | 245 | 5.3571 |
01:30 ET | 2000 | 5.35 |
01:32 ET | 1482 | 5.32 |
01:33 ET | 800 | 5.33 |
01:35 ET | 3563 | 5.34 |
01:37 ET | 100 | 5.34 |
01:39 ET | 100 | 5.34 |
01:42 ET | 2435 | 5.35 |
01:46 ET | 190 | 5.35 |
01:48 ET | 1300 | 5.35 |
01:50 ET | 6287 | 5.35 |
01:51 ET | 200 | 5.34 |
01:53 ET | 100 | 5.33 |
01:55 ET | 200 | 5.33 |
01:57 ET | 100 | 5.33 |
02:00 ET | 100 | 5.34 |
02:02 ET | 100 | 5.33 |
02:06 ET | 400 | 5.32 |
02:08 ET | 500 | 5.33 |
02:11 ET | 200 | 5.32 |
02:15 ET | 400 | 5.33 |
02:18 ET | 941 | 5.34 |
02:22 ET | 300 | 5.345 |
02:24 ET | 900 | 5.355 |
02:26 ET | 3980 | 5.36 |
02:27 ET | 2000 | 5.36 |
02:29 ET | 6348 | 5.35 |
02:33 ET | 100 | 5.33 |
02:38 ET | 300 | 5.35 |
02:40 ET | 100 | 5.345 |
02:42 ET | 900 | 5.35 |
02:44 ET | 400 | 5.35 |
02:45 ET | 200 | 5.35 |
02:47 ET | 664 | 5.35 |
02:49 ET | 200 | 5.35 |
02:51 ET | 1564 | 5.36 |
02:54 ET | 1351 | 5.35 |
02:56 ET | 100 | 5.35 |
03:00 ET | 305 | 5.35 |
03:02 ET | 219 | 5.35 |
03:03 ET | 100 | 5.34 |
03:09 ET | 1100 | 5.36 |
03:12 ET | 376 | 5.36 |
03:14 ET | 900 | 5.35 |
03:18 ET | 2976 | 5.35 |
03:21 ET | 200 | 5.35 |
03:23 ET | 2819 | 5.37 |
03:25 ET | 819 | 5.36 |
03:27 ET | 2109 | 5.35 |
03:32 ET | 100 | 5.34 |
03:34 ET | 5654 | 5.35 |
03:36 ET | 2173 | 5.3501 |
03:38 ET | 1847 | 5.35 |
03:39 ET | 1777 | 5.36 |
03:41 ET | 1407 | 5.345 |
03:43 ET | 3596 | 5.345 |
03:45 ET | 1000 | 5.3448 |
03:48 ET | 878 | 5.345 |
03:50 ET | 100 | 5.345 |
03:52 ET | 3360 | 5.34 |
03:54 ET | 5400 | 5.345 |
03:56 ET | 3114 | 5.35 |
03:57 ET | 11772 | 5.35 |
03:59 ET | 50999 | 5.34 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aldeyra Therapeutics Inc | 317.3M | -8.4x | --- |
Instil Bio Inc | 315.3M | -2.6x | --- |
Monte Rosa Therapeutics Inc | 312.4M | -2.3x | --- |
Korro Bio Inc | 312.3M | -1.1x | --- |
Lyell Immunopharma Inc | 312.3M | -1.5x | --- |
Inozyme Pharma Inc | 324.3M | -3.5x | --- |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $317.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.